Alembic Pharmaceuticals has received final USFDA approval for Fenofibric acid delayed-release capsules used for lowering high cholesterol and increasing good cholesterol. The approved product is therapeutically equivalent to the reference listed drug product Trilipix Delayed-Release capsules of Abbvie. Fenofibric acid delayed-release capsules are indicated as an adjunctive therapy to diet to reduce triglyceride (TG) in patients with hypertriglyceridemia and reduce elevated LDL-C, total cholesterol, and increase high-density lipoprotein (HDL) (good) cholesterol levels.
These capsules have an estimated market size of $93 million for 12 months to December 2016, according to IMS.
Company Profile : Alembic Pharmaceuticals Ltd
Leave a Reply